Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
24-26 February, 2026
Not Confirmed
Not Confirmed
17-21 January, 2026
Not Confirmed
Not Confirmed
21-22 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Tides Asia
Not Confirmed
Contact SupplierTides Asia
Industry Trade Show
Not Confirmed
24-26 February, 2026
Industry Trade Show
Not Confirmed
17-21 January, 2026
Industry Trade Show
Not Confirmed
21-22 January, 2026
Digital content
NEWS #PharmaBuzz
24 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sermonix-and-regor-announce-strategic-collaboration-to-optimize-regors-proprietary-rcard-platform-for-identification-of-novel-targets-and-therapeutics-302409362.html
10 Jan 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regor-releases-phase-2a-topline-results-for-rgt-075-an-oral-once-daily-small-molecule-glp-1r-agonist-and-begins-phase-2b-study-in-the-us-for-the-treatment-of-obesity-302348153.html
30 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regor-enters-into-a-definitive-purchase-agreement-for-genentech-to-acquire-regors-portfolio-of-next-generation-cdk-inhibitors-for-the-treatment-of-breast-cancer-302262174.html
08 Mar 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regor-initiates-phase-2-study-of-oral-once-daily-glp-1-agonist-rgt-075-for-the-treatment-of-obesity-302084213.html
07 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/regor-announces-promising-safety-and-single-agent-efficacy-data-evaluating-rgt-419b-in-hrher2--advanced-breast-cancer-patients-who-have-progressed-on-cdk46-inhibitors-and-endocrine-therapy-302009555.html
08 Feb 2023
// Fraiser Kansteiner FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/regor-gets-permission-glimpse-pfizers-fbi-communique-glp-1-trade-secrets-dispute
Drugs in Development
Details:
RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): RGT001-075
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2025
Lead Product(s) : RGT001-075
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 10, 2025
Details:
RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist, which is being evaluated in phase 2 clinical trials for the treatment of Obesity and overweight.
Lead Product(s): RGT-075
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2025
Lead Product(s) : RGT-075
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Regor Announces Phase 2a Data for RGT-075 and Begins Phase 2b Obesity Study
Details : RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist, which is being evaluated in phase 2 clinical trials for the treatment of Obesity and overweight.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2025
Details:
Genentech will acquire Regor's next-generation CDK inhibitors to strengthen its oncology pipeline, including RGT-419B, currently under evaluation for breast cancer treatment.
Lead Product(s): RGT-419B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Genentech
Deal Size: Undisclosed Upfront Cash: $850.0 million
Deal Type: Acquisition September 30, 2024
Regor Signs Agreement for Genentech to Acquire CDK Inhibitors for Breast Cancer
Details : Genentech will acquire Regor's next-generation CDK inhibitors to strengthen its oncology pipeline, including RGT-419B, currently under evaluation for breast cancer treatment.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $850.0 million
September 30, 2024
Details:
RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.
Lead Product(s): RGT-075
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 08, 2024
Lead Product(s) : RGT-075
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Regor Initiates Phase 2 Study of Once-Daily Oral GLP-1 Agonist RGT-075 for Obesity
Details : RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist, which is being evaluated in phase 2 clinical trials for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2024
Details:
RGT-419B is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): RGT-419B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 07, 2024
Details : RGT-419B is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 07, 2024
Details:
RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Lead Product(s): RGT001-075
Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 26, 2024
Lead Product(s) : RGT001-075
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of RGT001-075 in Adult Patients With Obesity
Details : RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 26, 2024
Details:
RGT-419B is a small molecule CDK4 inhibitor currently undergoing Phase I clinical trial evaluation with patients for treating HR-positive/HER2-negative Breast Neoplasms.
Lead Product(s): RGT-419B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2023
Details : RGT-419B is a small molecule CDK4 inhibitor currently undergoing Phase I clinical trial evaluation with patients for treating HR-positive/HER2-negative Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2023
Details:
RGT-264 Phosphate is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): RGT-264 Phosphate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 13, 2023
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Details : RGT-264 Phosphate is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 13, 2023
Details:
RGT-419B is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): RGT-419B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2022
Details : RGT-419B is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022
Details:
RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Lead Product(s): RGT001-075
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2022
Lead Product(s) : RGT001-075
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
Details : RGT001-075 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 25, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
